| 2022 | 2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) | EUROPEAN JOURNAL OF CANCER |
| 2022 | First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2022 | Lazertinib: on the Way to Its Throne
| YONSEI MEDICAL JOURNAL |
| 2022 | Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
| CLINICAL LUNG CANCER |
| 2022 | Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1
| BIOMEDICINE & PHARMACOTHERAPY |
| 2022 | DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | CLINICAL CANCER RESEARCH |
| 2022 | A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer | EXPERT OPINION ON INVESTIGATIONAL DRUGS |
| 2022 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer | CLINICAL LUNG CANCER |
| 2022 | Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
| JTO Clinical and Research Reports |
| 2022 | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study | LANCET ONCOLOGY |
| 2022 | Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
| THERANOSTICS |
| 2022 | Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial | JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2022 | A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
| JOURNAL OF THORACIC ONCOLOGY |
| 2022 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
| CLINICAL CANCER RESEARCH |
| 2022 | Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
| JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
| CLINICAL CANCER RESEARCH |
| 2022 | Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
| CURRENT ONCOLOGY |
| 2022 | Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
| 2022 | SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-oflife results from the phase 3 KEYNOTE-590 study | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer | FUTURE ONCOLOGY |
| 2022 | A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial | ANNALS OF ONCOLOGY |
| 2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |
| 2022 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer | CANCER RESEARCH |
| 2022 | Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC | CANCER DISCOVERY |
| 2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD) | CLINICAL LUNG CANCER |
| 2021 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC | JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
| JTO Clinical and Research Reports |
| 2021 | Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer | LUNG CANCER |
| 2021 | The promise of bispecific antibodies: Clinical applications and challenges | CANCER TREATMENT REVIEWS |
| 2021 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study | LANCET |
| 2021 | Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
| CLINICAL CANCER RESEARCH |
| 2021 | Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
| CLINICAL CANCER RESEARCH |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
| JTO Clinical and Research Reports |
| 2021 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
| CANCER MEDICINE |
| 2021 | Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
| CLINICAL LUNG CANCER |
| 2021 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study | LANCET ONCOLOGY |
| 2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
| 2021 | Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
| JTO Clinical and Research Reports |
http://orcid.org/0000-0002-5562-270X
(7401747804)
